JP2005518403A - アンドロゲンレセプターをブロックする化合物 - Google Patents
アンドロゲンレセプターをブロックする化合物 Download PDFInfo
- Publication number
- JP2005518403A JP2005518403A JP2003559448A JP2003559448A JP2005518403A JP 2005518403 A JP2005518403 A JP 2005518403A JP 2003559448 A JP2003559448 A JP 2003559448A JP 2003559448 A JP2003559448 A JP 2003559448A JP 2005518403 A JP2005518403 A JP 2005518403A
- Authority
- JP
- Japan
- Prior art keywords
- compounds
- cyclohexenone
- composition
- administered
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 102000001307 androgen receptors Human genes 0.000 title claims abstract description 19
- 108010080146 androgen receptors Proteins 0.000 title claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 230000000903 blocking effect Effects 0.000 claims abstract description 8
- FVIJFRPQQNCETD-UHFFFAOYSA-N 3-(5-methoxyheptyl)cyclohex-2-en-1-one Chemical compound CCC(OC)CCCCC1=CC(=O)CCC1 FVIJFRPQQNCETD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 208000002260 Keloid Diseases 0.000 claims abstract description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract description 4
- 210000001117 keloid Anatomy 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000037303 wrinkles Effects 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- -1 cyclohexenone compound Chemical class 0.000 abstract description 9
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical class O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 abstract description 7
- 230000001404 mediated effect Effects 0.000 abstract description 7
- 201000008482 osteoarthritis Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 description 10
- 239000003098 androgen Substances 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZFSPBKCXYUOIBG-UHFFFAOYSA-N 3-(5-ethoxyheptyl)cyclohex-2-en-1-one Chemical compound CCOC(CC)CCCCC1=CC(=O)CCC1 ZFSPBKCXYUOIBG-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 208000006784 Cutaneous Fistula Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/603—Unsaturated compounds containing a keto groups being part of a ring of a six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
- C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/713—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups a keto group being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
本発明は、患者において非必須アンドロゲンレセプターをブロックすることにより媒介される症状を処置するために有用である化合物に関する。
アンドロゲンは、挫瘡および雄性パターン禿のような種々の症状を引き起こすことで顕著な役割を演じていることが周知である。アンドロゲンに関係すると考えられているその他の症状には、ケロイド、接着、エラスチン合成、皺影響、および変形性関節症が含まれる。
本発明は、患者においてアンドロゲンレセプターをブロックするために用いられ得るシクロヘキセノン化合物に関する。この化合物は室温で安定であり、そして局所適用、経口、または内部投与のための種々の組成物で用いられ得る。
アンドロゲンレセプター部位をブロックするために用いられるいくつかの化合物は、ペンダントアルキル部分をもつ環式および二環式アルカノン環を利用している。これら化合物のいくつかでは、アルキル部分および環式の環は、炭素−炭素二重結合によって分離されている。代表的には、これらの化合物は、調製が困難で、そして室温および光に曝されるとき不安定である。これらの性質は、それらを、市販組成物および処置方法のための所望されない候補にしている。
Claims (10)
- RがCH3である、請求項1に記載の化合物。
- 哺乳動物においてアンドロゲンレセプター部位をブロックする方法であって、哺乳動物に有効用量の3−(5−メトキシヘプチル)−2−シクロヘキセノンを含む組成物を投与する工程を包含する、方法。
- 前記組成物が局所投与のために適合されており、そして局所的に投与される、請求項3に記載の方法。
- 前記組成物が経口的に投与される、請求項3に記載の方法。
- 前記組成物が内部に投与される、請求項3に記載の方法。
- 前記組成物が挫瘡に罹患した哺乳動物に投与される、請求項3に記載の方法。
- 前記組成物がケロイドに罹患した哺乳動物に投与される、請求項3に記載の方法。
- 前記組成物が雄性パターン禿に影響された哺乳動物に投与される、請求項3に記載の方法。
- 3−(5−メトキシヘプチル)−2−シクロヘキセノンを含む、哺乳動物に投与される組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34654502P | 2002-01-09 | 2002-01-09 | |
PCT/US2003/000534 WO2003059283A2 (en) | 2002-01-09 | 2003-01-09 | Compounds for blocking androgen receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005518403A true JP2005518403A (ja) | 2005-06-23 |
JP2005518403A5 JP2005518403A5 (ja) | 2006-03-02 |
Family
ID=23359898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003559448A Pending JP2005518403A (ja) | 2002-01-09 | 2003-01-09 | アンドロゲンレセプターをブロックする化合物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US6768026B2 (ja) |
EP (1) | EP1474122A4 (ja) |
JP (1) | JP2005518403A (ja) |
KR (1) | KR20040086262A (ja) |
CN (1) | CN1273121C (ja) |
AU (1) | AU2003235672A1 (ja) |
CA (1) | CA2473908A1 (ja) |
IL (1) | IL162849A0 (ja) |
WO (1) | WO2003059283A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507016A (ja) * | 2005-09-01 | 2009-02-19 | バイオフィジカ インコーポレイテッド | 新規なスキンケア組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6768026B2 (en) * | 2002-01-09 | 2004-07-27 | John P. Mamana | Compounds for blocking androgen receptors |
US20060263452A1 (en) * | 2005-05-17 | 2006-11-23 | Alwyn Dowell | Topical composition containing essential oils |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135849A (en) * | 1986-04-17 | 1992-08-04 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of androgens |
US5808139A (en) * | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
US5264619B1 (en) * | 1993-01-15 | 1996-05-14 | Cosmos Pharm Corp | Anti-androgenic cyclo and bicyclo alkenes |
WO1999008987A1 (en) | 1997-08-13 | 1999-02-25 | Meiji Milk Products Co., Ltd. | Cyclohexenone long-chain alcohol and medicament containing same |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US6768026B2 (en) * | 2002-01-09 | 2004-07-27 | John P. Mamana | Compounds for blocking androgen receptors |
-
2003
- 2003-01-09 US US10/338,889 patent/US6768026B2/en not_active Expired - Fee Related
- 2003-01-09 EP EP03729598A patent/EP1474122A4/en not_active Withdrawn
- 2003-01-09 JP JP2003559448A patent/JP2005518403A/ja active Pending
- 2003-01-09 CA CA002473908A patent/CA2473908A1/en not_active Abandoned
- 2003-01-09 WO PCT/US2003/000534 patent/WO2003059283A2/en not_active Application Discontinuation
- 2003-01-09 IL IL16284903A patent/IL162849A0/xx unknown
- 2003-01-09 CN CNB038020432A patent/CN1273121C/zh not_active Expired - Fee Related
- 2003-01-09 AU AU2003235672A patent/AU2003235672A1/en not_active Abandoned
- 2003-01-09 KR KR10-2004-7010712A patent/KR20040086262A/ko not_active Application Discontinuation
-
2004
- 2004-07-12 US US10/888,544 patent/US7211604B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009507016A (ja) * | 2005-09-01 | 2009-02-19 | バイオフィジカ インコーポレイテッド | 新規なスキンケア組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20040266884A1 (en) | 2004-12-30 |
CA2473908A1 (en) | 2003-07-24 |
WO2003059283A3 (en) | 2003-09-18 |
IL162849A0 (en) | 2005-11-20 |
US6768026B2 (en) | 2004-07-27 |
US20030153627A1 (en) | 2003-08-14 |
CN1620286A (zh) | 2005-05-25 |
WO2003059283A2 (en) | 2003-07-24 |
US7211604B2 (en) | 2007-05-01 |
KR20040086262A (ko) | 2004-10-08 |
AU2003235672A1 (en) | 2003-07-30 |
CN1273121C (zh) | 2006-09-06 |
EP1474122A4 (en) | 2006-04-19 |
EP1474122A2 (en) | 2004-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2335493C2 (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
CA2223403A1 (en) | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) n-¬(aminoiminomethyl)phenylalkyl|-azaheterocyclylamide compounds | |
CN104490884A (zh) | 治疗或预防炎症性皮肤疾病的化合物、制剂及方法 | |
WO2001039759A3 (en) | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
WO2001003690A1 (en) | Novel vasodilator cannabinoid analogs | |
HUP0204011A2 (en) | 1,2-diaryl benzimidazoles, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions for treating illnesses associated with a microglia activation | |
DE69927497D1 (de) | Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklylamidverbindungen | |
JPS63264421A (ja) | 高脂質血症治療剤 | |
CN1078887C (zh) | 用作消炎药的含硫的二叔丁基苯酚化合物 | |
PT92799B (pt) | Utilizacao de um agonista parcial de glicina b, nomeadamente um composto amino-isoxazolidina, para a preparacao de um medicamento empregue como antipsicotico e processo para a preparacao de uma composicao farmaceutica contendo o referido agonista | |
AU763111B2 (en) | Polycyclic 2-amino-thiazole systems, method for the production thereof and medicament containing said compounds | |
JP2005518403A (ja) | アンドロゲンレセプターをブロックする化合物 | |
RU2223951C2 (ru) | Сульфонамидзамещенные анеллированные пятичленные циклические соединения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции | |
BRPI0717919A2 (pt) | "agente profilático ou terapêutico para alopecia" | |
RU2002107421A (ru) | Алкоксизамещенные бензимидазольные соединения, содержащие их фармацевтические препараты и способы их применения | |
KR900000383A (ko) | 신규 화합물 | |
JPH08500120A (ja) | 置換アザスピランを用いる乾癬の治療方法 | |
JPH03291261A (ja) | ω−アミノ−フェニルアルカノニトリル誘導体 | |
JPH0653678B2 (ja) | アレルギ−性疾患治療剤 | |
JPS61172820A (ja) | カルシウム拮抗剤 | |
JPH03115221A (ja) | 抗ヒスタミン剤 | |
JPS59128326A (ja) | 抗真菌剤 | |
JP2005533082A (ja) | 近視の治療のためのgaba−cレセプターアンタゴニストの使用 | |
WO2000004015A1 (fr) | 1-4-dihydropyridines a groupe carbonyl benzodioxo comme inhibiteurs calciques | |
JP2002020289A (ja) | プロスタグランジンe2産生促進薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060110 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090414 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090421 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090514 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090521 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090807 |